Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one

Neuropharmacology

Volumn 57, Issue 4, 2009, Pages 438-445

  Fukuda, Junko ^a   Suzuki, Gentaroh ^a   Kimura, Toshifumi ^a   Nagatomi, Yasushi ^a   Ito, Satoru ^a   Kawamoto, Hiroshi ^a   Ozaki, Satoshi ^a   Ohta, Hisashi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

mGluR1 receptor antagonist; Point mutagenesis; Selective

Indexed keywords

3 CYCLOHEXYL 5 FLUORO 6 METHYL 7 (2 MORPHOLIN 4 YLETHOXY) 4H CHROMEN 4 ONE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5A; METABOTROPIC RECEPTOR ANTAGONIST; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DRUG SELECTIVITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CALCIUM; CHO CELLS; CHROMONES; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE TRANSFER TECHNIQUES; GLUTAMIC ACID; HUMANS; INTRACELLULAR SPACE; MOLECULAR SEQUENCE DATA; MORPHOLINES; POINT MUTATION; RECEPTORS, METABOTROPIC GLUTAMATE; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 68749094966     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.06.017     Document Type: Article

References (27)

1. Ballesteros J.A., Shi L., and Javitch J.A. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60 (2001) 1-19
2. Borhan B., Souto M.L., Imai H., Shichida Y., and Nakanishi K. Movement of retinal along the visual transduction path. Science (Wash DC) 288 (2000) 2209-2212
3. Carroll F.Y., Stolle A., Beart P.M., Voerste A., Brabet I., Mauler F., Joly C., Antonicek H., Bockaert J., Müller T., Pin J.P., and Prézeau L. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 59 (2001) 965-973
4. Conn P.J., and Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
5. Gasparini F., Kuhn R., and Pin J.P. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2 (2002) 43-49
6. Hemstapat K., Costa H., Nong Y., Brady A.E., Luo Q., Niswender C.M., Tamagnan G.D., and Conn P.J. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 322 (2007) 254-264
7. Horton R.M., Hunt H.D., Ho S.N., Pullen J.K., and Pease L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene (Amst) 77 (1989) 61-67
8. 2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J. Biol. Chem. 281 (2006) 21558-21565
9. Ito S., Satoh A., Nagatomi Y., Hirata Y., Suzuki G., Kimura T., Satow A., Maehara S., Hikichi H., Hata M., Kawamoto H., and Ohta H. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist. Bioorg. Med. Chem. 16 (2008) 9817-9829
10. Kew J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol. Ther. 104 (2004) 233-244
11. Kohara A., Toya T., Tmaura S., Watabiki T., Nagakura Y., Shitaka Y., Hayashibe S., Kawabata S., and Okada M. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J. Pharmacol. Exp. Ther. 315 (2005) 163-169
12. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol. 63 (2003) 1082-1093
13. Lavreysen H., Wouters R., Bischoff F., Pereira S.N., Langlois X., Blokland S., Somers M., Dillen L., and Lesage A.S.J. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47 (2004) 961-972
14. Litschig S., Gasparini F., Rueegg D., Stoehr N., Flor P.J., Vranesic I., Prézeau L., Pin J.P., Thomsen C., and Kuhn R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55 (1999) 453-461
15. Malherbe P., Kratochwil N., Knoflach F., Zenner M.T., Kew J.N.C., Kratzeisen C., Maerki H.P., Adam G., and Mutel V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 278 (2003) 8340-8347
16. Malherbe P., Kratochwil N., Zenner M.T., Piussi J., Diener C., Kratzeisen C., Fischer C., and Porter R.H.P. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-Methyl-6-(phenylethynyl)-pyridine. Mol. Pharmacol. 64 (2003) 823-832
17. de Mendonça F.L., da Fonseca P.C.A., Phillips R.M., Saldanha J.W., Williams T.J., and Pease J.E. Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. 280 (2005) 4808-4816
18. O'Brien J.A., Lemaire W., Wittmann M., Jacobson M.A., Ha S.N., Wisnoski D.D., Lindsley C.W., Schaffhauser H.J., Rowe B., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., and Williams Jr. D.L. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 309 (2004) 568-577
19. 3H] l-quisqualic acid and recombinant receptors. Z. Naturforsch. 57 (2002) 348-355
20. Pagano A., Rüegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezéau L., Carroll F., Pin J.P., Cambria A., Vranesic I., Flor P.J., Gasparini F., and Kuhn R. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1 a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 275 (2000) 33750-33758
21. 2+-sensing receptor. J. Biol. Chem. 278 (2003) 49487-49494
22. Ritzen A., Mathiesen J.M., and Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin. Pharmacol. Toxicol. 97 (2005) 202-213
23. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J.M., Bristow L.J., Verney M.A., and Daggett L.P. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64 (2003) 798-810
24. Spooren W., Ballard T., Gasparini F., Amalric M., Mutel V., and Schreiber R. Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioral characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 14 (2003) 257-277
25. Suzuki G., Kimura T., Satow A., Kaneko N., Fukuda J., Hikichi H., Sakai N., Maehara S., Kawagoe-Takaki H., Hata M., Azuma T., Ito S., Kawamoto H., and Ohta H. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]- N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J. Pharmacol. Exp. Ther. 321 (2007) 1144-1153
26. Vaidehi N., Schlyer S., Trabanino R.J., Floriano W.B., Abrol R., Sharma S., Kochanny M., Koovakat S., Dunning L., Liang M., Fox J.M., de Mendonça F.L., Pease J.E., Goddard III W.A., and Horuk R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J. Biol. Chem. 281 (2006) 27613-27620
27. Vanejevs M., Jatzke C., Renner S., Müller S., Hechenberger M., Bauer T., Klochkova A., Pyatkin I., Kazyulkin D., Aksenova E., Shulepin S., Timonina O., Haasis A., Gutcaits A., Parsons C.G., Kauss V., and Weil T. Positive and negative modulation of group I metabotropic glutamate receptors. J. Med. Chem. 51 (2008) 634-647